23rd May 2014 11:48
23 May 2014
LSE: VER
Vernalis Results of Annual General Meeting
Resolutions
Vernalis plc (LSE: VER) announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed.
All resolutions were approved on a show of hands. The number of proxy votes received for each resolution is set out below.
Resolution | For (including discretionary votes)* | Against* | Withheld | ||
Ordinary Resolutions (requires 50% majority) | |||||
1. That the audited accounts and related reports of the Directors and auditors for the year ended 31 December 2013 be received | 352,608,697 | (>99.99 %) | 2,327 | ( | 475 |
2. That the remuneration report contained within the report and accounts for the year ended 31 December 2013 be approved | 349,571,168 | (>99.14 %) | 3,018,508 | ( | 21,193 |
3. That Dr Baxter be re-elected as a director | 334,555,132 | (>99.99 %) | 13,038 | ( | 18,042,699 |
4. That Dr Fellner be re-elected as a director | 334,556,170 | (>99.99 %) | 11,959 | ( | 18,042,740 |
5. That Ms Ferguson be re-elected as a director | 334,560,765 | (>99.99 %) | 7,363 | ( | 18,042,741 |
6. That Mr Garland be re-elected as a director | 352,601,574 | (>99.99 %) | 5,840 | ( | 3,455 |
7. That PricewaterhouseCoopers LLP be reappointed auditors and the Directors be authorised to determine their remuneration | 321,385,145 | (>96.05 %) | 13,184,001 | ( | 18,041,723 |
8. That the Directors be authorised to allot shares | 352,569,652 | (>99.98 %) | 40,259 | ( | 958 |
Special Resolutions (requires 75% majority) | |||||
9. That the Directors be authorised to disapply pre-emption rights | 352,587,058 | (>99.99 %) | 22,787 | ( | 1,024 |
10. That General Meetings, other than Annual General Meetings, may be called on not less than 14 clear days' notice | 352,599,155 | (>99.99 %) | 11,421 | ( | 293 |
*NB: A vote withheld is not a vote in law and, is not counted in the calculation of the votes for or against a resolution. Therefore, the percentage of votes cast excludes withheld votes
On 23 May 2014, there were 442,261,426 Vernalis plc ordinary shares in issue. Shareholders are entitled to one vote per share held.
The full text of each resolution passed at the Annual General Meeting held earlier today, Friday 23 May 2014, is set out in the Notice of Annual General Meeting which is available for viewing on the Company's website at www.vernalis.com.
-- ends -
Enquiries:
Vernalis: | +44 (0) 118 938 0015 |
Ian Garland, Chief Executive Officer David Mackney, Chief Financial Officer
| |
Canaccord Genuity Limited (Nominated Adviser): | +44 (0) 20 7523 8350 |
Lucy Tilley Dr Julian Feneley Henry Fitzgerald-O'Connor
| |
Shore Capital (Joint Broker): | +44 (0) 20 7408 4090 |
Bidhi Bhoma Toby Gibbs
| |
Brunswick Group: | +44 (0) 20 7404 5959 |
Jon Coles
|
Notes to Editors
About Vernalis
Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as seven programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.
For further information about Vernalis, please visit www.vernalis.com
Related Shares:
Vernalis PLC